m+Medelevator.RU
← Поиск публикаций
Biology of reproduction · 2026

Glucocorticoid exposure disrupts vascular-immune interactions and impairs steroidogenesis in the fetal mouse testis†.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Matsuyama Satoko, Hudepohl Lauren, Matsuyama Kazuhiro, Li Shu-Yun, Ginugu Meghana, Gu Xiaowei, Kofron Matthew J, Ravindra Vikram, Shoda Tetsuo, DeFalco Tony

Аннотация

Antenatal corticosteroid (ACS) therapy, typically using dexamethasone (Dex), is a cornerstone of improving preterm infant survival by accelerating lung maturation. However, its systemic effects on other developing organs remain poorly understood. Here, we reveal a previously unrecognized impact of prenatal Dex exposure on fetal testis development, with implications for male reproductive health. Analysis of fetal testes from a Dex-based ACS mouse model revealed that Dex suppressed androgen synthesis by reducing Leydig cell number and downregulating steroidogenic pathways. Dex also activated immune programs, induced CD163+ M2c macrophages and IL-10 signaling, and promoted endothelial expansion. In response to aberrant pro-angiogenic signals, vascular architecture was disrupted: capillary density and pericyte gene expression declined, while blood vessel diameter increased. Transcriptomic analyses revealed downregulation of androgen response and cholesterol metabolism pathways, alongside upregulation of immune and coagulation signatures. Analyses of fetal ovaries revealed a sexually dimorphic and organ-specific effect of ACS treatment, in which ovarian gene expression during this window of development remained unaffected. Our findings uncover an immune-vascular mechanism linking prenatal Dex to impaired steroidogenesis, providing new insight into potentially broad effects of glucocorticoid exposure.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты